levothyroxine sodium
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypothyroidism
Conditions
Hypothyroidism
Trial Timeline
May 15, 2023 → Feb 22, 2024
NCT ID
NCT05823012About levothyroxine sodium
levothyroxine sodium is a phase 2 stage product being developed by Xeris Pharmaceuticals for Hypothyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT05823012. Target conditions include Hypothyroidism.
What happened to similar drugs?
2 of 2 similar drugs in Hypothyroidism were approved
Approved (2) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05823012 | Phase 2 | Completed |
Competing Products
5 competing products in Hypothyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Growth hormone + Growth hormone treatment and puberty | Eli Lilly | Approved | 35 |
| Armour Thyroid + Levothyroxine | AbbVie | Phase 2/3 | 45 |
| iodinated contrast agents | Bayer | Pre-clinical | 23 |
| Iohexol + Iodixanol + Iopromide + Ioversol | Bayer | Approved | 32 |
| Iodinated contrast agents | Bayer | Pre-clinical | 23 |